Introduction
============

Esophageal cancer is one of the most common malignancies worldwide, and in 2012, the incidence of esophageal cancer ranked 8th of all cancers ([@b1-ol-0-0-10768]). In 2015, cancer data from China revealed that the incidence and mortality rate of esophageal cancer were ranked 4th ([@b2-ol-0-0-10768]). Given that the early symptoms of esophageal cancer are not typical, and that the methods for early diagnosis are limited, 70--80% of patients cannot be diagnosed until reaching the intermediate or late stages of disease, when the opportunity for surgical treatment has been lost ([@b3-ol-0-0-10768]). Clinically, radiotherapy, chemotherapy and other comprehensive treatments are commonly used ([@b4-ol-0-0-10768]). A limited number of molecular and clinical studies have focused on the treatment of esophageal cancer in regards to the genes involved in immunization ([@b5-ol-0-0-10768]), and the majority of these studies have focused on adenocarcinoma at the junction of esophageal adenocarcinoma and gastric esophageal cancer, which is more frequently observed in Europe and the United States ([@b6-ol-0-0-10768],[@b7-ol-0-0-10768]).

Isobaric tags for relative and absolute quantitation (iTRAQ) is a high-throughput, high-sensitivity proteome quantification technique that is widely used for screening diagnostic and efficacy-related tumor markers ([@b8-ol-0-0-10768],[@b9-ol-0-0-10768]). In the present study, iTRAQ technology was first used to identify differentially expressed serum proteins associated with chemoradiotherapeutic efficacy in patients with esophageal squamous cell carcinoma (ESCC); the patients were recruited from different ethnic groups in the Xinjiang Uyghur Autonomous Region. Concurrently, functional tests including MTT assay, clonogenic and fluorescence assays, flow cytometry, Transwell assays and wound-healing assays were performed to determine the effect of the serum proteins with significantly differential expression, and RNA interference (RNAi) technology was used to silence the expression of ILK-associated gene; thus, their effects on the proliferation, apoptosis, invasion and migration of ESCC cells was observed, the results of which may be used as a reference for further research into the efficacy and prognostic mechanisms of esophageal cancer treatment.

Materials and methods
=====================

### Patients

A total of 60 patients with esophageal cancer who were treated at the First Affiliated Hospital of Xinjiang Medical University between July 2008 and April 2017 were recruited into the present study. the patients were recruited from different ethnic groups (25 cases from Han, 15 cases from Kazakh and 20 cases from Uygur). A control group containing 60 age- and sex-matched subjects was also recruited; these subjects underwent physical examination at the First Affiliated Hospital of Xinjiang Medical University. The clinicopathological characteristics of the patients are shown in [Table I](#tI-ol-0-0-10768){ref-type="table"}. The patients were recruited according to the following inclusion criteria: i) Pathologically confirmed advanced IIIB-IV esophageal cancer (using the esophageal cancer Tumor-Node-Metastasis staging criteria developed by the American Joint Committee on Cancer) ([@b10-ol-0-0-10768]) including those with postoperative recurrence and re-grading, or who were inoperable; ii) measurable lesions; iii) aged between 18--75 years of age (male or female) with a physical performance score (WHO Performance Status) ([@b11-ol-0-0-10768]) ≤0-2; iv) had received and tolerated radiotherapy or chemotherapy, and possessed an expected survival period ≥6 months; iii) no major organ dysfunction, with normal routine blood test results (white blood cell count, neutrophil percentage, neutrophil count, hemoglobin and platelet count) and normal liver, kidney and cardiac function; and iv) were able to understand the aim of the study and give informed consent for participation.

The exclusion criteria included: i) A history of malignancy at other sites; ii) patients who were pregnant or lactating; and iii) a history of uncontrollable psychosis, diagnosed by an expert neurologist. The recruited patients received platinum-based dual chemotherapy (docetaxel combined with cisplatin or paclitaxel combined with cisplatin), of paclitaxel (135--150 mg/m^2^) or docetaxel (75/m^2^) plus carboplatin (500 mg/time) or cis platinum (75 mg/m^2^), once every 3--4 weeks, for a total of 4--6 cycles. All patients underwent concurrent chemoradiotherapy, followed immediately by 4--6 cycles of chemotherapy. The radiotherapy program consisted of three-dimensional conformal irradiation or intensity-modulated radiation therapy, DT50-66 GY/25-33f (where the preventive and radical irradiation doses were 50 and 60--66 GY, respectively).

Short-term efficacy was categorized as complete remission (CR), partial remission (PR), stability disease (SD) and progression disease (PD) according to the response evaluation criteria in solid tumors (RECIST). The chemoradiotherapy-sensitive group was classified as CR+PR+SD, and the chemoradiotherapy-resistant group as PD.

Follow-up was conducted using the telephone, outpatient consultation and medical records once every 3 months, and the follow-up deadline was July 2017. During the follow-up period, the date of death was recorded for the patients that had died. For the patients who were lost to follow-up, the final follow-up time was recorded.

### Specimen collection and serum preparation

A total of 2 ml of fasting peripheral venous blood was collected from all participants. Following collection, the samples were stored at 4°C for 2--3 h until the blood had coagulated. The samples were then centrifuged at 3,000 × g for 10 min at 4°C to isolate the serum, and the supernatants were stored at −80°C until required.

### Screening and identification of target proteins

The serum samples were divided into eight groups: Normal control group; esophageal cancer patients prior to treatment group; esophageal cancer patients following treatment group; radiotherapy and chemotherapy sensitive group prior to treatment; chemoradiotherapy antagonist group prior to treatment; total survival period of 1 to 2 years; total survival period 2--3 years; and total survival \>3 years. Protein iTRAQ markers were used to identify differentially expressed proteins. After removing high-abundance proteins, such as albumin, immunoglobulin G and antitrypsin, a Bradford protein concentration determination assay was performed to determine the protein concentration. A total of 20 µg protein was loaded on a 12.5% gel and resolved using SDS-PAGE, and proteolysis and peptide quantification were performed. A total of 8 labeled peptide samples were re-dissolved in 100 µl of solvent (98% H~2~O, 0.1% formic acid) and 8 µl was injected into a Type C18 column size 100 mm × 75 µm, pore size 300A, particle size 5 µm. The samples were subjected to liquid phase separation using an Ultra Nano LC system (Thermo Fisher Scientific, Inc.) with a gradient of 5 to 80% buffer (98% acetonitrile, 2% H~2~O and 0.1% formic acid) for 3 h at 300 nl/min. Peptides were eluted using a gradient of 5--80% (v/v) acetonitrile in 0.1% formic acid over 45 min at a flow rate of 300 nl min^−1^ combined with a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Inc.) The eluates were directly entered the Q-Exactive mass spectrometer (Thermo Fisher Scientific, Inc.), set in positive ion mode and data-dependent manner with a full mass spectrometry scan from 350--2000 m/z, full scan resolution at 70,000 MS/MS scan resolution at 17,500 MS/MS scan, with a minimum signal threshold of 1^E+5^, isolation width at 2 Da. The sample was repeatedly identified 4 times. The raw mass spectrometry data was generated as a RAW file. ProteomeDiscoveral 4 software (Thermo Fisher Scientific, Inc.) was used to quantitatively analyze the peak intensity of the reported peptide ions. The results were scanned and filtered according to the misclassification rate ≤0.01. A ratio \>1.2 between the aforementioned groups was considered to indicate significant upregulation, and a ratio \<0.8 between groups was considered to indicate significant downregulation; P\<0.05.

### Integrin-linked kinase (ILK) siRNA target sequence screening and lentiviral vector construction

The ESCC EC9706 (DMEM supplemented with 10% FBS, 37°C, 5% CO~2~), ECa109 (RPMI-1640 supplemented with 10% FBS, cultured at 37°C, 5% CO~2~) and TE-1 (RPMI-1640 without Hepes supplemented with 10% FBS) cell lines were purchased from Shanghai Jikai Gene Chemical Technology Co., Ltd. Using the ILK gene as a template, multiple 19--21 nucleotide RNAi target sequences were designed using Chromas target sequence analysis and design software (Technelysium Pty, Ltd., version 2.1.3). siRNAs were designed for the target gene, the target sequence was 5′-CGAAGCTCAACGAGAATCA-3′, and the n.

Following RNAi target design, single-stranded DNA oligos containing interference sequences was synthesized and paired by annealing (90°C water bath for 15 min) to produce double-stranded DNA. These were subsequently ligated into the lentiviral vector GV115 (Shanghai Jikai GeneChem Co., Ltd.). Prepared TOP10 competent *E. coli* cells (GeneChem, Inc.) were transformed using the ligation products, and PCR was used to identify positive recombinant vectors. PCR and DNA sequencing were performed on the recombinant positive clones. The upstream primer of the positive clone was amplified using Taq Plus DNA Polymerase (Vazyme BioTech Co. Ltd.). The sequences of the primers used were: Forward, CCTATTTCCCATGATTCCTTCATA, and reverse GTAATACGGTTATCCACGCG. The thermocycling conditions were: 94°C for 3 min; followed by 22 cycles of 94°C for 30 sec; 55°C for 30 sec; 72°C for 30 sec; and a final extension of 72°C for 5 min. Sanger sequencing was used for verification. The sequencing results were compared with the correct clones for plasmid extraction. Bacteria containing the desired plasmids were transferred to 150 ml of LB liquid medium containing ampicillin, and cultured overnight at 37°C with shaking. The plasmids were extracted using an EndoFree Maxi Plasmid kit according to the manufacturer\'s protocols and the quality was determined. Plasmids of sufficient quality, as determined using NanoDrop 2000 (Thermo Fisher Scientific, Inc.), were used for virus packaging.

Following transfection, the TE-1 cells were cultured at 37°C, in a humidified incubator with 5% CO~2~. Lentiviral particles have different affinities for different cell lines ([@b12-ol-0-0-10768]). First, the target cells were pre-infected with a lentivirus, and different multiplicity of infections (MOI) gradients were used to evaluate the MOI of the target cells (Data not shown). A 48-well plate was used with a total medium volume of 200 µl. For the fluorescence-tagged lentivirus infection, the infection time point was determined in the preliminary results. Green fluorescent protein expression was observed under a fluorescence microscope (magnification, ×100). The fluorescence rate was 70--80%, the cell confluence was approximately 80%, the cells appeared healthy, the infection-efficiency was deemed sufficient, and cells were collected for further experimentation.

### Reverse transcription-quantitative PCR

RNA extraction and reverse transcription-quantitative PCR (RT-qPCR) was used to analyze tumor specimen. Total RNA was extracted using the TRIzol^®^ (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturers protocol. cDNA was synthesized from 2 µg total RNA using the M-MLV reverse transcriptase at 42°C for 1 h followed by 70°C for 10 min. GAPDH was used as the reference gene for RT-qPCR. The sequences used in the present study were ILK forward, 5′-GACGACATTTTCACTCAGTGCC-3′ and reverse, 5′-ACGGTTCATTACATTGATCCGTG-3′; GAPDH forward, 5′-TGACTTCAACAGCGACACCCA-3′ and reverse 5′-CACCCTGTTGCTGTAGCCAAA-3′. Gene-specific amplification of the 12 µl PCR mixture was performed using a ABI 7500HT real-time PCR system (Thermo Fisher Scientific, Inc.). The thermocycling condition were: 94°C for 3 min; followed by 22 cycles of 94°C for 30 sec, 94°C for 60 sec and 72°C for 60 sec; followed by a final extension step at 72°C for 5 min. DNA concentration was approximately doubled following each cycle of denaturation, annealing and elongation. The cycle quantification (Cq) of each sample was calculated, and the relative expression of the gene was calculated using the 2^−ΔΔCq^ method ([@b13-ol-0-0-10768]).

### Cell proliferation assay

Trypsinized TE-1 cells in the logarithmic growth phase were resuspended in complete medium and plated in 96-well culture plates at 2×10^3^ cells/well. Cells were incubated at 37°C in a humidified atmosphere with 5% CO~2~. The Celigo^®^ cytometer (Nexclom Bioscience) was used to detect cell growth once a day for 5 days. By adjusting the input parameters of the analysis settings using Cellometer Auto 2000 Cell Viability Counter (Nexcelom Bioscience), the number of cells with green fluorescence was calculated and a 5-day cell proliferation curve was generated.

### MTT assay

Cells in the logarithmic growth phase were harvested, homogenized into a single-cell suspension, and 2×10^3^ cells/well were plated in 96-well cell culture plates. Cells were incubated at 37°C in a humidified incubator with 5% CO~2~. Subsequently, 20 µl MTT (5 mg/ml) was added to each well, and the cells were incubated for a further 4 h. The supernatant was discarded, 150 µl DMSO was added and the samples were shaken for 2--5 min to fully dissolve the formazan crystals. Absorbance was determined at 490 nm using a microplate reader. Time was used as the abscissa and the optical density was used as the ordinate for plotting the cell growth curve.

### Cell colony formation assay

After transfection, TE-1 cells in the logarithmic growth phase were trypsinized in each experimental group, resuspended in complete medium and counted. The cells were seeded into a 6-well culture plate (500 cells/well) and the cultured for 11 days with a media change once every 3 days. The cells were fixed with 1 ml 4% paraformaldehyde at 37°C for 30--60 min and stained with 500 µl Giemsa staining solution (Shanghai Dingguo Biotechnology Co., Ltd.) at 37°C for 10--20 min and the colonies were subsequently counted.

### Apoptosis detection using flow cytometry

Following transfection, cells in the logarithmic growth from each experimental group were harvested and resuspended in complete culture medium. The cells were collected by centrifugation at 1,300 × g for 5 min at 4°C, the supernatant was discarded, and the cell pellet was washed with pre-cooled D-Hanks (Shanghai Research Extension Biotechnology Co., Ltd.) solution at 4°C. The cell pellet was washed with binding buffer (Shanghai Suo Laibao Biotechnology Co., Ltd,) stained with 10 µl Annexin V-APC and analyzed using a flow cytometer and Guava^®^ InCyte version 8HT (Luminex Corporation).

### Transwell migration and invasion assay

A total of 1×10^5^ cells/well were seeded on a Matrigel membrane in the upper chamber of a 24-well Transwell plates for the invasion assay. For the migration assay cells were seeded without Matrigel. In the bottom chamber, 600 µl medium containing 30% FBS was added. Cells were incubated under standard culture conditions for 20 h. Following invasion or migration, cells which had not invaded or migrated were removed and the remaining cells were stained with 800 µl of Giemsa staining solution onto the lower surface of the membrane at 37°C for 3--5 min. The membranes were visualized under a light microscope at ×200 and imaged to determine differences in the migratory and invasive capacity. A total of 9 random microscopic fields for each well were counted.

### Wound-healing assay

Transfected cells (\~4×10^4^) from each group were added to 96-well plates, and cultured until \~90% confluent. The following day, the concentration of serum in the medium was reduced, and a wound was created in the monolayer. The cells were gently rinsed 2--3 times with serum-free medium, and incubated at 37°C in a humidified incubator with 5% CO~2~. Images were captured at 0, 8 and 24 h using a fluorescence microscope (magnification, ×200). Images were obtained after 0, 8 and 24 h using a light microscope (magnification, ×200). The width of the scratched area in the picture at each time point of each wound was obtained using the W value function of Adobe Photoshop (Adobe Systems Europe, Ltd. version CC 2018). Wound closure was measured relative to the starting wound width by dividing the wound width at each time point by the width at the start.

### Statistical analysis

Statistical data analysis was conducted using SPSS version 19.0 software (IBM Corp.). A Student\'s t-test was used to compare differences between two groups. Comparisons between shILK and shCtrl were initially analyzed using an F-test (homogeneity of variance test). If the F-test value is \>0.05, a t-test value was obtained using an equal variance two-sample test. If the F-test value was \<0.05, the heteroscedasticity was doubled. The sample test yielded the t-test value. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Evaluation of clinical efficacy

According to RECIST, 36 cases were included in the CR+PR+SD group by analyzing medical data from outpatient visits records, which accounted for 60% of the total cases; 24 cases were classified as PD, 40% of the total.

### Differentially expressed serum proteins in patients with ESCC

From the patients with ESCC, 46 differentially expressed proteins were identified prior to chemoradiotherapy, compared to those identified in the control subjects: 26 proteins were upregulated and 20 were downregulated ([Tables II](#tII-ol-0-0-10768){ref-type="table"} and [III](#tIII-ol-0-0-10768){ref-type="table"}). Volcano maps show that differential expression of serum proteins between patients with ESCC (before chemoradiotherapy) and those in the control group ([Fig. 1](#f1-ol-0-0-10768){ref-type="fig"}).

Significantly differentially expressed proteins were compared between the chemoradiotherapy-sensitive and -resistant groups and between the survival times of patients with ESCC, classified as either 1--2, 2--3 and \>3 years ([Tables IV](#tIV-ol-0-0-10768){ref-type="table"} and [V](#tV-ol-0-0-10768){ref-type="table"}). The volcano plots show differential expression of serum proteins between patients with esophageal cancer of different severities group ([Fig. 2](#f2-ol-0-0-10768){ref-type="fig"}).

Among the differentially-expressed proteins, ILK appeared most frequently at all outcomes in patients with esophageal cancer. This protein was upregulated in patients with ESCC before chemoradiotherapy, compared with the control group \[ratio (r)=4.386; P\<0.05\], and downregulated in the chemoradiotherapy-sensitive group compared with the chemoradiotherapy-resistant group (r=0.587, P\<0.05; survival period \>3 years compared with a survival period of 1--2 years; r=0.633, P\<0.05; [Table VI](#tVI-ol-0-0-10768){ref-type="table"}).

### The effect of ILK expression on cell proliferation, apoptosis, invasion and migration in ESCC

The ILK mRNA expression levels were determined in the TE-1 ESCC cell line ([Fig. 3](#f3-ol-0-0-10768){ref-type="fig"}). Lentivirus was used for target cell transfection, and the results confirmed a transfection efficiency of \>80%. Following transfection, there were no noticeable changes in the morphology and the cells appeared healthy. After siRNA lentivirus infection, the mRNA expression level of ILK was determined using RT-qPCR. The results showed that the expression of ILK in TE-1 cells of the shILK group was successfully inhibited compared with the shCtrl group (P\<0.05), and that the knockdown efficiency was 88% ([Fig. 4](#f4-ol-0-0-10768){ref-type="fig"}).

To examine the effect of ILK gene ablation on cell proliferation, cell number was determined using fluorescence and MTT assays three days post-transfection with shRNA lentivirus. After five days, the proliferation rate was decreased in the shILK group compared with the shCtrl group (P\<0.05) in both assays ([Figs. 5](#f5-ol-0-0-10768){ref-type="fig"} and [6](#f6-ol-0-0-10768){ref-type="fig"}). ILK gene-silencing was shown to inhibit the proliferation of TE-1 cells.

Flow cytometry was used to detect the impact of ILK gene inhibition on apoptosis, five days following shRNA lentivirus transfection. The degree of apoptosis in TE-1 cells of the shILK group increased significantly (P\<0.01), indicating that the ILK gene is significantly associated with apoptosis in these cells ([Fig. 7](#f7-ol-0-0-10768){ref-type="fig"}).

In addition, the impact of ILK gene ablation on cell colony formation was also detected. The number of TE-1 cell colonies in the shILK group was significantly lower than that of the shCtrl group (P\<0.01), suggesting that the ILK gene is significantly associated with the colony forming ability of TE-1 cells ([Fig. 8](#f8-ol-0-0-10768){ref-type="fig"}).

Migration and invasion assays were used to detect the effect of ILK-knockdown on migration and invasion capacities of TE-1 cells, three days post-transfection with shRNA lentivirus. The migration and invasion abilities of TE-1 cells in the shILK group were significantly inhibited compared with those of the shCtrl group (P\<0.01), suggesting that ILK gene-silencing inhibits the migration and invasion abilities of TE-1 cells ([Figs. 9](#f9-ol-0-0-10768){ref-type="fig"} and [10](#f10-ol-0-0-10768){ref-type="fig"}).

The effect of ILK gene-silencing on TE-1 cell migration was also detected using a wound-healing assay three days post-transfection with shRNA lentivirus. The migratory ability at 8 and 24 h in the shILK group compared with the shCtrl group at the same time point was significantly reduced (P\<0.01), suggesting that ILK is significantly associated with the migratory ability of TE-1 cells ([Fig. 11](#f11-ol-0-0-10768){ref-type="fig"}).

Discussion
==========

According to China\'s esophageal cancer and the USA National Cancer Comprehensive Network guidelines, advanced ESCC is primarily treated with chemoradiotherapy-based comprehensive treatment ([@b14-ol-0-0-10768]). However, resistance to chemoradiotherapy is the primary reason for its limited effect, which results in poor overall efficacy ([@b15-ol-0-0-10768]). Studies in China and worldwide have suggested that the abnormal expression of molecular markers, such as cell division cycle 25C ([@b16-ol-0-0-10768]), suppressor of cytokine signaling 1 ([@b17-ol-0-0-10768]), single-minded homolog 2 ([@b18-ol-0-0-10768]) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α ([@b19-ol-0-0-10768]) in esophageal cancer tissues has significance when predicting the efficacy of esophageal cancer chemotherapy. However, to date, there are no established molecular markers for predicting the efficacy of esophageal cancer chemotherapy.

In the present study, iTRAQ technology was used to screen serum differentially-expressed proteins associated with the efficacy of chemoradiotherapy in ESCC. The results revealed that ILK expression levels in patients with esophageal cancer (before chemoradiotherapy) were higher compared with those in the control subjects, and that ILK expression in chemoradiotherapy-sensitive patients was reduced compared with that in the chemoradiotherapy-resistant group. These findings indicated that the abnormal expression of ILK may be associated with the occurrence and development of ESCC, and that ILK may be involved in the regulation of chemoradiotherapy sensitivity, and thus closely associated with sensitivity to chemoradiotherapy in patients with esophageal cancer. Based on these results, the effect of ILK expression on ESCC cells characteristics was investigated. To the best of our knowledge, the present study shows for the first time that ILK gene-silencing significantly inhibits the proliferation, invasion and migration, and promotes apoptosis in ESCC TE-1 cells.

ILK is a serine/methionine protein kinase that was discovered by Hannigan *et al* ([@b20-ol-0-0-10768]) in a double yeast hybridization screening experiment in human cDNA libraries, using the β1 integrin cytoplasmic domain. As a key kinase in integrin and growth factor receptor signaling pathways, ILK regulates cell growth, differentiation, adhesion and apoptosis, and is closely associated with tumor formation, invasion, and metastasis ([@b21-ol-0-0-10768]). Furthermore, ILK upregulation has been reported to occur in bladder ([@b22-ol-0-0-10768]) and colon cancer ([@b23-ol-0-0-10768]). Regarding ILK research in esophageal cancer, Driver and Veale ([@b24-ol-0-0-10768]) used RT-PCR to study the expression and subtypes of ILK, epidermal growth factor and transforming growth factor-β1 in five human ESCC cell lines of South African origin. The effect of ILK expression suggests that epidermal growth factor and transforming growth factor-β1 may regulate ILK expression in ESCC.

The present study suggested that cell proliferation was reduced when ILK expression was inhibited in TE-1 cells, as shown by fluorescence detection, MTT and colony formation assays. These findings suggest that ILK may promote the proliferation of TE-1 cells. Abnormal expression of the ILK gene may be an important factor to increase the malignancy of ESCC. Apoptosis is closely associated with the occurrence, development and prognosis of various diseases, particularly tumors ([@b25-ol-0-0-10768]). The effect of ILK gene inhibition on apoptosis in TE-1 cells was assessed using flow cytometry. The apoptotic rate of TE-1 cells was increased relative to the control group following ILK knockdown. Therefore, ILK inhibits apoptosis and may be an important factor for the proliferation of TE-1 cells. Furthermore, wound-healing assays revealed that ILK inhibited the migratory ability of TE-1 cells compared with that of the control group. It was hypothesized that ILK may promote the migration of TE-1 cells, leading to enhanced biological characteristics and increasing the risk of distant metastasis in malignant tumors. To simulate the invasive tumor cell environment, a Transwell chamber was utilized. The results showed that ILK silencing inhibited the invasive properties of TE-1 cells, and therefore, ILK may promote the invasion of ESCC cells.

In addition, studies have reported that abnormal expression of ILK affects the chemoradiotherapeutic sensitivity of tumor cells. Duxbury *et al* ([@b26-ol-0-0-10768]) found that overexpression of ILK increased the chemotherapeutic resistance of pancreatic cancer cells to gemcitabine, and that ILK knockout increased the sensitivity of caspase-3-mediated apoptosis to gemcitabine. A previous study by Lanvin *et al* ([@b27-ol-0-0-10768]) showed that ILK regulated mitochondrial death caused by radiotherapy via the hypoxia inducible factor-1α and survivin pathways, thereby altering the radiosensitivity of glioma cells. These studies suggest that ILK increases tumor cell resistance to radiotherapy. However, there is no experimental indication that ILK influences the chemoradiotherapeutic sensitivity of esophageal cancer.

In the present study, iTRAQ technology was used to identify the molecular marker ILK, which is predictive of the efficacy of esophageal cancer chemotherapy. It was revealed for the first time that the inhibition of ILK expression promoted the biological characteristics of ESCC, and increased the degree of tumor malignancy. However, the present study has several limitations and was not able to determine the mechanism by which ILK promotes the characteristics of ESCC; therefore, further research is required. Moreover, proteins associated with metastasis were not investigated, and the lack of animal studies and the investigation of proteins associated with epithelial-mesenchymal transition are also limitations of the present study. In addition, 2-dimensional migration and invasion cannot fully recapitulate the metastatic phenotype. At the same time, ILK is a potential mediator of tumor chemoradiotherapy resistance. Therefore, in the future, an in-depth understanding of the molecular mechanisms of resistance to esophageal cancer chemoradiotherapy, and the exploration of new strategies for targeting chemoradiotherapy resistance, will have important clinical implications for improving treatment efficacy and patient survival.
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![Reverse transcription-quantitative PCR results of ILK expression levels indicate that ILK is expressed in EC9706, Eca-109 and TE-1 esophageal squamous cell carcinoma cells. GAPDH was used as the internal control. ILK, integrin-linked kinase.](ol-18-04-4114-g02){#f3-ol-0-0-10768}

![Comparison of mRNA expression levels between TE-1 cells transfected with small interfering RNA lentivirus and the control group. \*\*P\<0.01. ILK, integrin-linked kinase; ctrl, control.](ol-18-04-4114-g03){#f4-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell proliferation using the Celigo^®^ cytometer.\*P\<0.05. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control.](ol-18-04-4114-g04){#f5-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell proliferation, determined using an MTT assay.\*P\<0.05. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control; OD, optical density.](ol-18-04-4114-g05){#f6-ol-0-0-10768}

![Effects of ILK knockdown on apoptosis in esophageal squamous-cell carcinoma cells, using flow cytometry. \*\*P\<0.01. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control.](ol-18-04-4114-g06){#f7-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell colony formation. \*\*P\<0.01. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control.](ol-18-04-4114-g07){#f8-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell migration, using Transwell assays. \*\*P\<0.01. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control. Magnification, ×200.](ol-18-04-4114-g08){#f9-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell invasion, using a Matrigel assay. \*\*P\<0.01. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control. Magnification, 200×.](ol-18-04-4114-g09){#f10-ol-0-0-10768}

![Effects of ILK knockdown on esophageal squamous-cell carcinoma cell migration, using wound-healing assays. sh, short hairpin; ILK, integrin-linked kinase; ctrl, control. \*\*P\<0.01 vs. the respective shCtrl. Magnification, 200×.](ol-18-04-4114-g10){#f11-ol-0-0-10768}

###### 

Clinicopathological characteristics of the patients.

  Clinicopathological characteristic   n     Proportion, %
  ------------------------------------ ----- ---------------
  Age                                        
    ≤60                                32    53.33
    \>60                               28    46.67
  Sex                                        
    Male                               35    58.33
    Female                             25    41.67
  Involved region                            
    Neck section                         7   11.67
    Upper thoracic                     11    18.33
    Middle thoracic                    23    38.33
    Lower thoracic                     19    31.67
  Clinical stage                             
    Phase III                          38    63.33
    Phase IVA                          22    36.67

###### 

Upregulated differentially expressed proteins in the serum of Chinese patients with esophageal cancer, before chemoradiotherapy.

  Accession ID                                           Protein                                    Gene       Ratio   P-value
  ------------------------------------------------------ ------------------------------------------ ---------- ------- -----------------
  P23528                                                 Cofilin-1                                  CFL1       1.532   1.16789×10^−3^
  P06753                                                 Tropomyosin α-3 chain                      TPM3       1.633   1.76099×10^−4^
  P08185                                                 Corticosteroid-binding globulin            SERPINA6   1.753   3.01686×10^−5^
  P67936                                                 Tropomyosin α-4 chain                      TPM4       1.759   3.61117×10^−10^
  Q15746                                                 Myosin light chain kinase, smooth muscle   MYLK       1.76    2.32945×10^−2^
  P02749                                                 β-2-glycoprotein 1                         APOH       1.794   1.68655×10^−9^
  P02750                                                 Leucine-rich α-2-glycoprotein              LRG1       1.828   1.89684×10^−2^
  P0DJI8                                                 Serum amyloid A-1 protein                  SAA1       1.836   3.64567×10^−9^
  P01019                                                 Angiotensinogen                            AGT        1.855   2.96144×10^−12^
  P01009                                                 α-1-antitrypsin                            SERPINA1   1.944   3.41166×10^−65^
  P68871                                                 Hemoglobin subunit β                       HBB        1.951   3.77869×10^−12^
  P05155                                                 Plasma protease C1 inhibitor               SERPING1   2.027   1.03898×10^−10^
  P05543                                                 Thyroxin-binding globulin                  SERPINA7   2.063   7.87217×10^−6^
  P19652                                                 α-1-acid glycoprotein 2                    ORM2       2.065   1.57516×10^−7^
  P01023                                                 α-2-macroglobulin                          A2M        2.209   2.24553×10^−69^
  P04217                                                 α-1B-glycoprotein                          A1BG       2.241   7.01006×10^−14^
  P0DJI9                                                 Serum amyloid A-2 protein                  SAA2       2.254   7.76843×10^−16^
  P01011                                                 α-1-antichymotrypsin                       SERPINA3   2.363   1.59357×10^−28^
  P02768                                                 Serum albumin                              ALB        2.477   1.89258×10^−3^
  P02741                                                 C-reactive protein                         CRP        2.517   1.59305×10^−91^
  P01861                                                 Immunoglobulin heavy constant γ4           IGHG4      2.584   2.27127×10^−3^
  P02787                                                 Serotransferrin                            TF         2.89    5.56713×10^−82^
  P02790                                                 Hemopexin                                  HPX        2.999   5.72798×10^−31^
  P25311^[a](#tfn1-ol-0-0-10768){ref-type="table-fn"}^   Zinc-α-2-glycoprotein                      AZGP1      3.122   5.90489×10^−8^
  Q13418^[a](#tfn1-ol-0-0-10768){ref-type="table-fn"}^   Integrin-linked protein kinase             ILK        4.386   3.69519×10^−31^
  P02763^[a](#tfn1-ol-0-0-10768){ref-type="table-fn"}^   α-1-acid glycoprotein 1                    ORM1       5.234   5.50575×10^−16^

Significantly differentially expressed protein. The results are compared with the those of the control group.

###### 

Downregulated differentially expressed proteins in the serum of Chinese patients with esophageal cancer, before chemoradiotherapy.

  Accession ID                                           Protein                                      Gene       Ratio   P-value
  ------------------------------------------------------ -------------------------------------------- ---------- ------- ------------------
  P02776^[a](#tfn2-ol-0-0-10768){ref-type="table-fn"}^   Platelet factor 4                            PF4        0.469   2.12173×10^−21^
  Q08380^[a](#tfn2-ol-0-0-10768){ref-type="table-fn"}^   Galectin-3-binding protein                   LGALS3BP   0.483   4.59282×10^−40^
  P08697^[a](#tfn2-ol-0-0-10768){ref-type="table-fn"}^   α-2-antiplasmin                              SERPINF2   0.495   2.5819×10^−30^
  P10720                                                 Platelet factor 4 variant                    PF4V1      0.533   1.24972×10^−7^
  P02751                                                 Fibronectin                                  FN1        0.536   1.72558×10^−11^°
  Q16610                                                 Extracellular matrix protein 1               ECM1       0.557   8.40852×10^−11^
  Q13103                                                 Secreted phosphoprotein 24                   SPP2       0.565   2.66878×10^−7^
  P27918                                                 Properdin                                    CFP        0.582   1.6419×10^−16^
  P00488                                                 Coagulation factor XIII A chain              F13A1      0.594   1.3398×10^−14^
  Q5SYB0                                                 FERM and PDZ domain-containing protein 1     FRMPD1     0.607   2.98852×10^−12^
  Q15485                                                 Ficolin-2                                    FCN2       0.608   1.51904×10^−17^
  O43852                                                 Calumenin                                    CALU       0.61    4.42339×10^−8^
  P01860                                                 Immunoglobulin heavy constant γ3             IGHG3      0.639   1.20085×10^−16^
  P04114                                                 Apolipoprotein B-100                         APOB       0.641   4.42101×10^−7^°
  O43866                                                 CD5 antigen-like                             CD5L       0.642   6.51383×10^−21^
  Q92954                                                 Proteoglycan 4                               PRG4       0.651   3.50318×10^−5^
  P04004                                                 Vitronectin                                  VTN        0.658   4.9004×10^−179^
  P04180                                                 Phosphatidylcholine-sterol acyltransferase   LCAT       0.665   5.75865×10^−10^
  P04196                                                 Histidine-rich glycoprotein                  HRG        0.666   5.28207×10^−20^
  Q96IY4                                                 Carboxypeptidase B2                          CPB2       0.667   8.99551×10^−8^

Significantly differentially expressed protein. The results are compared with the those of the control group.

###### 

Differentially expressed proteins between Chinese chemoradiotherapy-sensitive and chemoradiotherapy-resistant patients with esophageal cancer.

  Accession ID                                           Protein                                 Gene     Ratio   P-value           Regulation
  ------------------------------------------------------ --------------------------------------- -------- ------- ----------------- ------------
  P02763                                                 α-1-acid glycoprotein 1                 ORM1     0.348   1.00117×10^−13^   Down
  P00738                                                 Haptoglobin                             HP       0.456   4.58182×10^−21^   Down
  P01833^[a](#tfn3-ol-0-0-10768){ref-type="table-fn"}^   Polymeric immunoglobulin receptor       PIGR     0.526   1.30577×10^−2^    Down
  P04217                                                 α-1B-glycoprotein                       A1BG     0.653   1.50285×10^−20^   Down
  P25311                                                 Zinc-α-2-glycoprotein                   AZGP1    0.656   2.97886×10^−6^    Down
  P08571                                                 Monocyte differentiation antigen CD14   CD14     0.657   1.63716×10^−3^    Down
  P11597                                                 Cholesteryl ester transfer protein      CETP     0.661   9.93464×10^−6^    Down
  Q13418                                                 Integrin-linked kinase                  ILK      0.587   9.41968×10^−4^    Down
  A0M8Q6^[a](#tfn3-ol-0-0-10768){ref-type="table-fn"}^   Ig λ-7 chain C region                   IGLC7    1.886   3.64692×10^−3^    Up
  Q15848^[a](#tfn3-ol-0-0-10768){ref-type="table-fn"}^   Adiponectin                             ADIPOQ   1.836   9.54065×10^−9^    Up
  P59665^[a](#tfn3-ol-0-0-10768){ref-type="table-fn"}^   Neutrophil defensin 1                   DEFA1    1.927   1.16427×10^−2^    Up

Significantly differentially expressed protein.

###### 

Differentially expressed proteins between Chinese patients with esophageal cancer with \>3 years and 1--2 years survival rates.

  Accession ID                                           Description                             Gene       Ratio   P-value           Regulation
  ------------------------------------------------------ --------------------------------------- ---------- ------- ----------------- ------------
  P05154^[a](#tfn4-ol-0-0-10768){ref-type="table-fn"}^   Plasma serine protease inhibitor        SERPINA5   0.421   4.45068×10^−18^   Down
  Q92496                                                 Complement factor H-related protein 4   CFHR4      0.558   5.80371×10^−11^   Down
  P59665                                                 Neutrophil defensin 1                   DEFA1      0.58    5.35236×10^−3^    Down
  P62805^[a](#tfn4-ol-0-0-10768){ref-type="table-fn"}^   Histone H4                              HIST1H4A   0.584   1.79658×10^−6^    Down
  P68431^[a](#tfn4-ol-0-0-10768){ref-type="table-fn"}^   Histone H3.1                            HIST1H3A   0.596   1.23326×10^−3^    Down
  P20160                                                 Azurocidin                              AZU1       0.606   2.56589×10^−4^    Down
  Q13418^[a](#tfn4-ol-0-0-10768){ref-type="table-fn"}^   Integrin-linked kinase                  ILK        0.633   1.45967×10^−2^    Down
  P02776                                                 Platelet factor 4                       PF4        0.664   5.87470×10^−17^   Down
  P49720                                                 Proteasome subunit β type-3             PSMB3      1.552   1.44523×10^−2^    Up
  P0DJI9^[a](#tfn4-ol-0-0-10768){ref-type="table-fn"}^   Serum amyloid A-2 protein OS=Homo       SAA2       1.68    1.57258×10^−13^   Up

Significantly differentially expressed protein.

###### 

Expression of ILK in Chinese patients with esophageal cancer of different severities.

  Group                                                                     Accession   Description              Gene   Ratio   P-value           Regulation
  ------------------------------------------------------------------------- ----------- ------------------------ ------ ------- ----------------- ------------
  Esophageal cancer patients prior to treatment vs. control group           Q13418      Integrin-linked kinase   ILK    4.386   3.69519×10^−31^   Up
  Chemoradiotherapy-sensitive group vs. chemoradiotherapy-resistant group   Q13418      Integrin-linked kinase   ILK    0.587   9.41968×10^−4^    Down
  Survival group \>3 years vs. survival group 1--2 years                    Q13418      Integrin-linked kinase   ILK    0.633   1.45967×10^−2^    Down

Upregulated ratio \>1.2, downregulated ratio \<0.8.
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